Your genome is stubborn. It sits there while medical knowledge rushes past it. A test ordered in one decade might be asked a better question in the next. MyOme, a clinical genomics company founded in 2017, has organized its business around that awkward timing. Sequence the whole genome from a blood draw or cheek swab. Interpret the parts a clinician needs now. Keep the possibility of returning to the data later.
- MyOme sells provider-ordered genomic reports for preventive risk, medication response, and rare disease diagnosis.
- Its Atlas platform looks for future risks; Zenith investigates existing, often elusive conditions.
- One sequence can support more than one report, while clinical factors and genetic counseling help turn results into decisions.
- Price depends on the test, insurance, and assistance. Whether earlier insight improves outcomes is the larger question now being tested.
The founders were not trying to make the genome itself novel. Matthew Rabinowitz, Akash Kumar, and Kate Im were trying to make it useful in ordinary clinical life. Rabinowitz had co-founded Natera; Kumar brought medical and scientific leadership; Im led research. Their stated premise was that people should own portable genetic data and receive insights when those insights matter, rather than be trapped inside one frozen report.
A panel has an expiration date
The conventional genetic test often begins with a shortlist: these genes, for this condition, today. That is sensible when the question is narrow. It is less satisfying when a family needs to know about heart disease, cancer risk, a medication, and an unexplained illness at different moments in life. MyOme sequences across the genome and then makes separate clinical reports from the resulting data. The company says a sample can be re-queried as symptoms change or the science improves.
There is a practical elegance to the arrangement. A patient does not need to understand three billion DNA letters to benefit. A clinician orders a specific test, the lab analyzes the relevant data, and the result comes back with a patient-friendly explanation and access to genetic counseling. The company reports average 30x whole-genome coverage, meaning each base is read about 30 times, to support its clinical analysis. The sequencing is performed in a CLIA-certified, CAP-accredited laboratory.
Two products, two kinds of uncertainty
MyOme now presents two testing platforms. Atlas is for proactive care. Its Curated Screen examines up to 151 genes linked to more than 40 conditions. Medication Response covers genetic findings relevant to more than 70 medicines. Other reports estimate risk for coronary artery disease, type 2 diabetes, breast cancer, and prostate cancer. These are prompts for a medical conversation, not diagnoses or predictions of fate.
Zenith faces a different problem: the family already knows something is wrong, but does not know why. It offers rare disease exome, genome, and copy-number analysis. In 2026 MyOme added long-read methylation analysis for eligible cases, a way to investigate gene regulation as well as the DNA sequence itself. Natera began offering Zenith through its clinical network. That relationship is revealing: a specialized analysis company can build the method, while a partner supplies established access to clinicians.
The same genome can therefore act as a map for prevention or as a detective’s file. The difference is in the question. That is MyOme’s cleanest answer to the market crowded with gene panels, consumer ancestry kits, and other clinical laboratories: it is selling an ongoing interpretation layer on top of a comprehensive sequence. Its rival is sometimes another lab, sometimes a narrower test, and sometimes the habit of waiting until illness gives medicine no choice.
The risk score meets the chart
A polygenic risk score adds up the small effects of many genetic variants. On its own, it can feel suspiciously like a weather forecast without a location. MyOme blends that inherited signal with clinical measures used by doctors already, including established calculators for breast and cardiovascular risk. The company also models ancestry continuously, including mixed ancestry, instead of forcing a patient into one self-reported group. That design addresses a real historical weakness of genetic prediction: datasets and models have often represented some populations better than others.
In coronary artery disease research presented in 2023, MyOme reported that its integrated model found up to 27 additional future cases per 1,000 people in a borderline or intermediate clinical-risk group, compared with a standard clinical model. A 2026 paper examined whether combined genetic and clinical predictions stay stable across modeling choices. These are studies of prediction. The harder test is whether clinicians act on the information wisely, patients benefit, and the system spends less. MyOme’s planned prospective preventive-health trial, supported by a 2025 Illumina collaboration and investment, is intended to build that evidence. A projected national savings figure in the partnership announcement is a model, not a realized saving.
“The whole genome backbone enables the delivery of future genomic reports on-demand for a lifetime of insights.”Premal Shah, then CEO, in MyOme's 2022 Series B announcement
Who pays for the second question?
MyOme is not a kit to toss into an online cart. A healthcare provider orders its tests. Patients and families receive the results; clinicians, health systems, and employer-benefits programs form the routes to them. The company raised $23 million in a 2022 Series B, taking disclosed funding at the time above $36 million. Since then it has widened distribution through Natera, employer programs with Novi Health and Thatch, and primary-care work with Ms.Medicine.
There is no public, universal sticker price for a MyOme test. The patient’s bill depends on test type, insurance, and financial-assistance eligibility. For diagnostic testing, MyOme Access offers an out-of-pocket estimator and case-by-case aid; the company also describes self-pay options and payment plans. A patient should ask the ordering provider which report is needed, whether the insurer requires prior authorization, and what the estimated out-of-pocket cost will be. Those mundane questions can matter as much as the elegant model.
MyOme’s argument is easy to copy in miniature: collect a rich measurement once, preserve it with the patient’s consent, and make each later interpretation answer a specific clinical question. The difficult part is earning the right to use it. A risk score needs validation in the people who will receive it. A laboratory result needs a counselor or clinician who can explain its limits. A business built on reanalysis needs privacy controls and a bill someone will pay. MyOme’s founding promise of individual data ownership gives that last point moral force, but the proof will be in the workflow.
There is something almost old-fashioned about the premise. The company is asking medicine to keep a good record and revisit it when better questions arise. The genome may stay the same. The responsibility to interpret it does not.